Medtronic settles antitrust charges in Avecor acquisition
This article was originally published in Clinica
Executive Summary
Medtronic has agreed to divest Avecor's non-occlusive arterial pump technology to settle US antitrust charges that its $106 million acquisition of the company would reduce competition.